Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Case management to improve adherence for HIV-infected patients receiving antiretroviral therapy in Ethiopia: a micro-costing study.
Marseille EA, Kevany S, Ahmed I, Feleke G, Graham B, Heller T, Kahn JG, Reyes M.
Cost Eff Resour Alloc. 2011 Dec 20;9:18.
Related citations
Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.
Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP.
J Manag Care Pharm. 2009 Jan-Feb;15(1):32-41.
Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.
Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D.
J Acquir Immune Defic Syndr. 2001 May 1;27(1):14-9.
The cost of providing comprehensive HIV treatment in PEPFAR-supported programs.
Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, Ellerbrock TV, Blandford JM.
AIDS. 2011 Sep 10;25(14):1753-60.
Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries.
Galárraga O, Wirtz VJ, Figueroa-Lara A, Santa-Ana-Tellez Y, Coulibaly I, Viisainen K, Medina-Lara A, Korenromp EL.
Pharmacoeconomics. 2011 Jul;29(7):579-99. doi: 10.2165/11586120-000000000-00000. Review.
Antiretroviral Therapy in the Real World : Population-Based Pharmacoeconomic Analysis of Administration of Anti-HIV Regimens to 990 Patients.
Sabbatani S, Manfredi R, Biagetti C, Chiodo F.
Clin Drug Investig. 2005;25(8):527-35.
Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands.
Hubben GA, Bos JM, Veltman-Starkenburg CA, Stegmeijer S, Finnern HW, Kappelhoff BS, Simpson KN, Tramarin A, Postma MJ.
Cost Eff Resour Alloc. 2007 Nov 22;5:15.
Medication therapy management: 10 years of experience in a large integrated health care system.
Ramalho de Oliveira D, Brummel AR, Miller DB.
J Manag Care Pharm. 2010 Apr;16(3):185-95.
The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization.
Sansom SL, Anthony MN, Garland WH, Squires KE, Witt MD, Kovacs Andrea A, Larsen RA, Valencia R, Pals SL, Hader S, Weidle PJ, Wohl AR.
AIDS Patient Care STDS. 2008 Feb;22(2):131-8.
Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E.
J Manag Care Pharm. 2008 Mar;14(2):164-75.
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP.
Pharmacoeconomics. 2004;22(6):389-411. Review.
Cost-effectiveness of highly active antiretroviral therapy in South Africa.
Badri M, Maartens G, Mandalia S, Bekker LG, Penrod JR, Platt RW, Wood R, Beck EJ.
PLoS Med. 2006 Jan;3(1):e4. Epub 2005 Dec 6.
Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre.
Beck EJ, Mandalia S, Griffith R, Beecham J, Walters MD, Boulton M, Miller DL.
Pharmacoeconomics. 2000 Jan;17(1):53-69.
Variation in patient routine costliness in U.S. psychiatric facilities.
Cromwell J, Drozd EM, Gage B, Maier J, Richter E, Goldman HH.
J Ment Health Policy Econ. 2005 Mar;8(1):15-28.
The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis.
Cleary SM, McIntyre D, Boulle AM.
Cost Eff Resour Alloc. 2006 Dec 6;4:20.
What is the cost of getting the price wrong?
Beck EJ, Beecham J, Mandalia S, Griffith R, Walters MD, Boulton M, Miller DL.
J Public Health Med. 1999 Sep;21(3):311-7.
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
Health Technol Assess. 2001;5(32):1-195. Review.
Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
Ruof J, Dusek A, DeSpirito M, Demasi RA.
Clin Drug Investig. 2007;27(7):469-79.
Evaluation of molecular techniques in prediction and diagnosis of cytomegalovirus disease in immunocompromised patients.
Szczepura A, Westmoreland D, Vinogradova Y, Fox J, Clark M.
Health Technol Assess. 2006 Apr;10(10):1-176.
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A.
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on